Screener
ADMA Biologics ADMA ADMA Bio Manufacturing — Business Acquisitions Pro Forma Revenue
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by ADMA Biologics in its filing.
Tagged under the XBRL concept us-gaap:BusinessAcquisitionsProFormaRevenue.
The source filing: ADMA Biologics’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 5:16 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001140361-26-031445
| (in thousands) | ADMA Bio Manufacturing | Plasma Collection Centers | Total |
|---|---|---|---|
| Revenues | $$123,637 | $723 | 124,360 |
| Cost of product revenue | 37,564 | 554 | 38,118 |
| Research and development | 6,014 | - | 6,014 |
| Plasma center operating expenses | - | 1,026 | 1,026 |
| Gain on sale of plasma centers | - | - | - |
| Selling, marketing and distribution | 7,634 | - | 7,634 |
| Depreciation and amortization expense | 1,281 | 499 | 1,780 |
| General and administrative expense | 8,340 | - | 8,340 |
Item 1. Financial Statements.
FAQ
- What is ADMA Biologics's ADMA bio manufacturing — business acquisitions pro forma revenue?
- ADMA Biologics (ADMA) reported ADMA bio manufacturing — business acquisitions pro forma revenue of $123.64M in Q2 2026.
- What does ADMA bio manufacturing — business acquisitions pro forma revenue mean?
- Represents the hypothetical total revenue of the BioManufacturing segment as if recent business acquisitions had occurred at the beginning of the reporting period. This metric helps investors evaluate the combined revenue-generating capacity of the segment following inorganic growth activities.
Ask your AI about ADMA Biologics's adma bio manufacturing — business acquisitions pro forma revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude